The EBiSC team is working hard to implement improvements in how EBiSC operates. Due to some short-term disruption, please get in touch via Contact@EBiSC.org if the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe.

PFIZi013-A

RCi215, RCFB59 C9

iPSC line

Immediately available for distribution*
*Once all legal and processing details completed
Timepoint: Confluency
Magnification: 4x
Timepoint: Confluency
Magnification: 10x
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name PFIZi013-A
Alternative name(s)
RCi215, RCFB59 C9
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
UCLi004-B
(RCFB60c7, RCi177)
Donor's gene variants:
C9orf72, C9orf72
Donor diseases:
Amyotrophic lateral sclerosis
Frontotemporal dementia
UCLi004-C
(RCi172, RCFB60c2)
Donor's gene variants:
C9orf72, C9orf72
Donor diseases:
Amyotrophic lateral sclerosis
Frontotemporal dementia
UCLi004-A
(RCi173, RCFB60c6)
Donor's gene variants:
C9orf72, C9orf72
Donor diseases:
Amyotrophic lateral sclerosis
Frontotemporal dementia
CHDIi001-A
(#1c8, CHDI-90002149)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi003-A
(#3c1, CHDI-90002151)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi005-A
(#5c4, CHDI-90002153)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi020-A
(#20c2, CHDI-90002168)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi022-A
(#22c1, CHDI-90002170)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi034-A
(#105c1, CHDI-90002182)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease
CHDIi055-A
(#133c5, CHDI-90002203)
Donor's gene variants:
HTT, HTT
Donor diseases:
Huntington disease

Provider

Depositor Pfizer Limited - Pfizer (PFIZ)
Distributors
EBiSC

External Databases

hPSCreg PFIZi013-A
BioSamples SAMEA4343623
Cellosaurus CVCL_IJ00
Wikidata Q54947267

General Information

This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no

Donor Information#

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Lou Gehrig disease
  • Charcot disease
  • ALS
Genetic variants
TARDBP (target)
1p36.2
NM_007375.3:c.1144G>A
NP_031401.1:p.Ala382Thr
p.A382T mutation in TARDBP

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA4343604

hIPSC Derivation#

General

Source cell type
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
Passage number reprogrammed 4

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch

Culture medium mTeSR1
Passage method EDTA
Surface coating Matrigel
O2 concentration 21
CO2 concentration 5
Temperature 37 °C
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SSEA-1
No
SSEA-4
Yes
TRA 1-60
Yes
SSEA-1
No
SSEA-4
Yes
TRA 1-60
Yes
POU5F1 (OCT-4)
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
CXCR4
Unknown
SOX17
Unknown
Gata6
Unknown
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
VIM
Unknown
DCN
Unknown
MIXL1
Unknown
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
PAX6
Yes
NeuroD1
Yes
HES5
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Sterility

Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
No autosomal or sex chromosome aneuplodies were detected
Passage number: 26
Karyotyping method: BoBs

Other Genotyping (Cell Line)